Beirne Wealth Consulting Services LLC Reduces Holdings in Altimmune, Inc. (NASDAQ:ALT)

Beirne Wealth Consulting Services LLC cut its position in Altimmune, Inc. (NASDAQ:ALT) by 2.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 294,458 shares of the company’s stock after selling 8,342 shares during the quarter. Altimmune accounts for 0.8% of Beirne Wealth Consulting Services LLC’s portfolio, making the stock its 29th largest position. Beirne Wealth Consulting Services LLC owned 0.41% of Altimmune worth $2,123,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ALT. Larson Financial Group LLC bought a new stake in shares of Altimmune in the third quarter worth $31,000. 180 Wealth Advisors LLC acquired a new position in Altimmune during the 4th quarter worth $78,000. PFG Investments LLC bought a new stake in shares of Altimmune in the 4th quarter worth about $96,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Altimmune in the 4th quarter valued at about $109,000. Finally, Stifel Financial Corp lifted its position in shares of Altimmune by 77.4% during the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock worth $109,000 after purchasing an additional 7,746 shares during the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Trading Up 1.8 %

Shares of NASDAQ:ALT opened at $6.49 on Wednesday. Altimmune, Inc. has a fifty-two week low of $5.28 and a fifty-two week high of $14.84. The company’s 50-day moving average price is $7.19 and its 200 day moving average price is $7.18.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ALT. Stifel Nicolaus initiated coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. UBS Group assumed coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Wednesday, February 5th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $20.83.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.